Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SAGE | Common Stock | Award | $0 | +2.85K | +33.03% | $0.00 | 11.5K | Feb 3, 2023 | Direct | F1, F2 |
transaction | SAGE | Common Stock | Tax liability | -$43.3K | -980 | -8.54% | $44.16 | 10.5K | Feb 3, 2023 | Direct |
Id | Content |
---|---|
F1 | On February 10, 2021, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 9,500 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on February 3, 2023, resulting in the vesting of the PSUs as to 2,850 shares. |
F2 | Reflects beneficial ownership balance which includes 221 shares purchased on June 30, 2022 and 432 shares purchased on December 31, 2022, each under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan. |